X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2987) 2987
indazoles - pharmacology (2431) 2431
animals (2193) 2193
male (1383) 1383
humans (1271) 1271
rats (1163) 1163
pharmacology & pharmacy (800) 800
enzyme inhibitors - pharmacology (775) 775
mice (772) 772
nitric oxide (597) 597
nitric oxide synthase - antagonists & inhibitors (552) 552
female (519) 519
neurosciences (443) 443
indazoles - chemistry (427) 427
rats, sprague-dawley (422) 422
chemistry, medicinal (414) 414
dose-response relationship, drug (407) 407
oncology (347) 347
biochemistry & molecular biology (341) 341
rats, wistar (341) 341
cell line, tumor (328) 328
antineoplastic agents - pharmacology (324) 324
indazoles - therapeutic use (315) 315
7-nitro indazole (309) 309
structure-activity relationship (298) 298
indazoles - chemical synthesis (287) 287
ng-nitroarginine methyl ester - pharmacology (274) 274
nitric oxide - metabolism (267) 267
inhibition (266) 266
cancer (245) 245
indazoles - administration & dosage (243) 243
expression (238) 238
nitric-oxide synthase (236) 236
7-nitroindazole (229) 229
protein kinase inhibitors - pharmacology (217) 217
in vitro techniques (211) 211
analysis (209) 209
nitric oxide synthase type i (208) 208
nitric oxide synthase - metabolism (207) 207
brain (205) 205
activation (202) 202
nitric oxide - physiology (200) 200
pyrazoles - pharmacology (192) 192
imidazoles - pharmacology (190) 190
in-vivo (187) 187
cell proliferation - drug effects (179) 179
molecular structure (177) 177
rat (175) 175
nitric oxide synthase (174) 174
indazoles - pharmacokinetics (172) 172
apoptosis (171) 171
disease models, animal (171) 171
time factors (170) 170
cell biology (168) 168
cells, cultured (166) 166
chemistry, organic (161) 161
signal transduction - drug effects (156) 156
cells (155) 155
sulfonamides - pharmacology (155) 155
arginine - pharmacology (152) 152
l-arginine (150) 150
apoptosis - drug effects (147) 147
models, molecular (139) 139
neurons (135) 135
indoles - pharmacology (134) 134
physiology (134) 134
article (132) 132
research (132) 132
indazoles - metabolism (130) 130
blood pressure - drug effects (129) 129
in-vitro (127) 127
mice, inbred c57bl (126) 126
adult (125) 125
phosphorylation (125) 125
middle aged (124) 124
inhibitors (123) 123
cell survival - drug effects (122) 122
signal transduction (122) 122
nitric oxide synthase type i - antagonists & inhibitors (120) 120
indazoles (118) 118
yc-1 (118) 118
drug synergism (117) 117
indazole (117) 117
synthase (117) 117
cell line (116) 116
indazoles - adverse effects (112) 112
kinetics (111) 111
drug interactions (109) 109
potent (108) 108
nitric-oxide (106) 106
axitinib (105) 105
pharmacology (104) 104
drug design (103) 103
inhibitor (103) 103
derivatives (102) 102
guanylate cyclase - metabolism (102) 102
angiogenesis (101) 101
administration, oral (100) 100
proteins (100) 100
aged (99) 99
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3104) 3104
Japanese (25) 25
Chinese (23) 23
German (23) 23
Russian (18) 18
Hungarian (6) 6
French (5) 5
Italian (5) 5
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Communications, ISSN 2041-1723, 12/2017, Volume 8, Issue 1, pp. 1090 - 19
Journal Article
PSYCHOPHARMACOLOGY, ISSN 0033-3158, 10/2016, Volume 233, Issue 21-22, pp. 3685 - 3709
Rationale AKB48 and its fluorinate derivate 5F-AKB48 are two novel synthetic cannabinoids belonging to a structural class with an indazole core structure. They... 
EXTRACELLULAR DOPAMINE | PRIMARY SOMATOSENSORY CORTEX | SAFETY PHARMACOLOGY | AGGRESSIVE-BEHAVIOR | PREPULSE INHIBITION | PSYCHIATRY | EVOKED ACTIVITY | AKB48 | JWH-018 | NEUROSCIENCES | MASS-SPECTROMETRY | Cannabinoids | NOCICEPTIN/ORPHANIN FQ TRANSMISSION | 5F-AKB48 | Microdialysis | Sensorimotor responses | Synthetic cannabinoids | Delta-THC | PHARMACOLOGY & PHARMACY | NUCLEUS-ACCUMBENS SHELL | Behavior | RECEPTOR AGONIST | Humans | Nucleus Accumbens - metabolism | Motor Activity - drug effects | Male | Receptor, Cannabinoid, CB2 - antagonists & inhibitors | Cannabinoid Receptor Agonists - pharmacology | Seizures - chemically induced | Cannabis | Piperidines - pharmacology | Cannabinoid Receptor Antagonists - pharmacology | Catalepsy - chemically induced | Pain Threshold - drug effects | Behavior, Animal - drug effects | Indoles - pharmacology | Reflex, Abnormal - drug effects | Dronabinol - pharmacology | Dopamine - metabolism | Adamantane - analogs & derivatives | Pyrazoles - pharmacology | Binding, Competitive | Adamantane - pharmacology | Naphthalenes - pharmacology | Indazoles - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Receptor, Cannabinoid, CB2 - metabolism | Animals | Mice | In Vitro Techniques | Nucleus Accumbens - drug effects | Aggression - drug effects | Pharmacology, Experimental | Research | Neurochemistry | Psychotropic drugs | Neurology | Pharmacology | Rodents | Index Medicus
Journal Article
Journal Article
Neuropharmacology, ISSN 0028-3908, 06/2016, Volume 105, pp. 630 - 638
Journal Article
British Journal of Cancer, ISSN 0007-0920, 05/2014, Volume 110, Issue 10, pp. 2479 - 2488
Background: Mesothelioma is a notoriously chemotherapy-resistant neoplasm, as is evident in the dismal overall survival for patients with those of... 
ACTIVATION | GROWTH-FACTOR-RECEPTOR | FACTOR SCATTER FACTOR | MALIGNANT PLEURAL MESOTHELIOMA | PHASE-II | tyrosine kinases | ANTITUMOR-ACTIVITY | MET RECEPTOR | PI3K/AKT/MDM2 | PI3K/AKT/mTOR | INHIBITION | ONCOLOGY | C-MET | mesothelioma | Mesothelioma - pathology | Nitriles - pharmacology | Humans | Neoplasm Proteins - physiology | Receptor Protein-Tyrosine Kinases - physiology | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Quinolines - pharmacology | MAP Kinase Signaling System | TOR Serine-Threonine Kinases - antagonists & inhibitors | raf Kinases - physiology | RNA Interference | TOR Serine-Threonine Kinases - physiology | Antineoplastic Agents - pharmacology | Chromones - pharmacology | Everolimus | Butadienes - pharmacology | Sirolimus - analogs & derivatives | RNA, Small Interfering - pharmacology | Morpholines - pharmacology | Imidazoles - pharmacology | Enzyme Activation - drug effects | Sulfonamides - pharmacology | Sirolimus - pharmacology | Indazoles - pharmacology | Signal Transduction - drug effects | Mesothelioma - enzymology | Cell Line, Tumor | Phosphatidylinositol 3-Kinases - physiology | Protein Kinase Inhibitors - pharmacology | Cell Cycle - drug effects | Drug Screening Assays, Antitumor | Index Medicus | Translational Therapeutics | PI3K | mTOR | MDM2 | AKT
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2014, Volume 50, Issue 17, pp. 3021 - 3028
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 06/2009, Volume 329, Issue 3, pp. 928 - 937
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 2006, Volume 531, Issue 1, pp. 87 - 95
The possible participation of the nitric oxide (NO)-cyclic GMP-protein kinase G (PKG) pathway on gabapentin-induced spinal antiallodynic activity was assessed... 
Pinacidil | Gabapentin | Nitric oxide | Protein kinase G | Diazoxide | Guanylyl cyclase | K + channel opener | Neuropathic pain | channel opener | SENSITIVE POTASSIUM CHANNELS | nitric oxide | TACTILE ALLODYNIA | K+ channel opener | RANDOMIZED CONTROLLED-TRIAL | NERVE INJURY | VASCULAR SMOOTH-MUSCLE | guanylyl cyclase | neuropathic pain | gabapentin | diazoxide | pinacidil | RABBIT VENTRICULAR MYOCYTES | PHARMACOLOGY & PHARMACY | protein kinase G | UP-REGULATION | CALCIUM-CHANNEL | PERIPHERAL ANTINOCICEPTIVE ACTION | Analgesics - pharmacology | Okadaic Acid - pharmacology | Potassium Channels - physiology | Pinacidil - administration & dosage | Cyclic GMP-Dependent Protein Kinases - antagonists & inhibitors | Glyburide - pharmacology | Time Factors | Charybdotoxin - pharmacology | Oxadiazoles - pharmacology | Potassium Channel Blockers - pharmacology | Spinal Nerves - injuries | Spinal Nerves - physiopathology | Enzyme Inhibitors - pharmacology | Cyclohexanecarboxylic Acids - administration & dosage | Rats | gamma-Aminobutyric Acid - pharmacology | Indazoles - pharmacology | NG-Nitroarginine Methyl Ester - chemistry | Cyclic GMP - metabolism | Signal Transduction - drug effects | Pain - physiopathology | Nitric Oxide Synthase - metabolism | Carbazoles - pharmacology | Amines - pharmacology | Diazoxide - administration & dosage | Cyclic GMP - antagonists & inhibitors | Diazoxide - pharmacology | Rats, Wistar | Stereoisomerism | Nitric Oxide Synthase - antagonists & inhibitors | gamma-Aminobutyric Acid - administration & dosage | Apamin - pharmacology | Cyclic GMP-Dependent Protein Kinases - metabolism | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Amines - administration & dosage | Female | Indoles - pharmacology | Injections, Spinal | NG-Nitroarginine Methyl Ester - pharmacology | Pinacidil - pharmacology | Vasodilator Agents - pharmacology | Pain - prevention & control | Nitric Oxide - antagonists & inhibitors | Analgesics - administration & dosage | Animals | Cyclohexanecarboxylic Acids - pharmacology | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Nitric Oxide - metabolism | Vasodilator Agents - administration & dosage | Index Medicus
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, pp. e0125021 - e0125021
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance.... 
COLON-CANCER | MELANOMA | MEK INHIBITION | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | SYNTHETIC LETHAL INTERACTION | RESISTANCE | BRAF | KINASE INHIBITOR | BETA-CATENIN | EGFR | Triazoles - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Aza Compounds - pharmacology | Cell Line, Tumor - drug effects | Indazoles - administration & dosage | Quinolines - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Melanoma - genetics | Indoles - pharmacology | Pyrimidinones - pharmacology | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Aza Compounds - administration & dosage | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | beta Catenin - metabolism | beta Catenin - genetics | Indazoles - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Triazoles - pharmacology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oxazoles - administration & dosage | Oximes - pharmacology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Oxazoles - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - pharmacology | Sulfonamides - administration & dosage | Drug therapy, Combination | Drug resistance | Drug therapy | Health aspects | Analysis | Melanoma | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2011, Volume 117, Issue 12, pp. 3286 - 3293
We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly... 
AML | YOUNGER PATIENTS | INTENSIVE CHEMOTHERAPY | SERUM-LEVELS | TYROSINE KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | MUTATIONS | HEMATOLOGY | CLINICAL-RESPONSE | APLASTIC-ANEMIA | STEM-CELL MOBILIZATION | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Staurosporine - analogs & derivatives | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Membrane Proteins - pharmacology | Phenylurea Compounds | Benzenesulfonates - pharmacology | Multicenter Studies as Topic | Protein Kinase Inhibitors - antagonists & inhibitors | Membrane Proteins - physiology | Inhibitory Concentration 50 | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Membrane Proteins - blood | Pyridines - therapeutic use | Antineoplastic Agents - antagonists & inhibitors | Leukemia, Myeloid, Acute - pathology | Cells, Cultured | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Piperazines - therapeutic use | Piperazines - pharmacology | Randomized Controlled Trials as Topic | Indazoles - pharmacology | Drug Antagonism | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Carbazoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carbazoles - pharmacology | Indazoles - therapeutic use | Staurosporine - pharmacology | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2007, Volume 6, Issue 7, pp. 2012 - 2021
With the development of targeted therapeutics, especially for small-molecule inhibitors, it is important to understand whether the observed in vivo efficacy... 
kinase inhibitor | Pharmacodynamics | pazopanib | angiogenesis | VEGF | TARGET | ONCOLOGY | FACTOR RECEPTORS | EXPRESSION | CANCER | TUMORS | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Pyrimidines - blood | Humans | Fibroblast Growth Factor 2 - pharmacology | Antineoplastic Agents - administration & dosage | Indazoles - administration & dosage | Sulfones - pharmacology | Neovascularization, Pathologic - pathology | Phosphotyrosine - metabolism | Dose-Response Relationship, Drug | Sulfonamides - blood | Inhibitory Concentration 50 | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Cornea - pathology | Phosphorylation - drug effects | Sulfones - blood | Vascular Endothelial Growth Factor A - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Pyrimidines - administration & dosage | Pyrimidines - pharmacology | Sulfones - pharmacokinetics | Sulfonamides - pharmacology | Protein Kinase Inhibitors - blood | Sulfonamides - pharmacokinetics | Indazoles - pharmacology | Protein Kinase Inhibitors - administration & dosage | Indazoles - blood | Animals | Indazoles - pharmacokinetics | Cell-Free System | Mice, Nude | Antineoplastic Agents - blood | Cell Line, Tumor | Pyrimidines - pharmacokinetics | Mice | Protein Kinase Inhibitors - pharmacology | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Index Medicus
Journal Article
BBA - Molecular Cell Research, ISSN 0167-4889, 08/2018, Volume 1865, Issue 8, pp. 1073 - 1087
Journal Article